UVR-B-induced NKR-1 Expression in Ocular Tissues is blocked by Substance P Receptor Antagonist Fosaprepitant in the Exposed as well as Unexposed Partner Eye

References

• Nolan TM, DiGirolamo N, Sachdev NH, Hampartzoumian T, Coroneo MT, Wakefield D. The role of ultraviolet irradiation and heparin-binding epidermal growth factor-like growth factor in the pathogenesis of pterygium. Am J Pathol. 2003;162(2):567–574. doi:https://doi.org/10.1016/S0002-9440(10)63850-3.
   PubMed Web of Science ®Google Scholar
• Meyer LM, Löfgren S, Holz FG, Wegener A, Söderberg P. Bilateral cataract induced by unilateral UVR-B exposure – evidence for an inflammatory response. Acta Ophthalmol. 2013;91(3):236–242. doi:https://doi.org/10.1111/aos.2013.91.issue-3.
   PubMed Web of Science ®Google Scholar
• Di Girolamo N, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci. 2006;47(6):2430–2437. doi:https://doi.org/10.1167/iovs.05-1130.
   PubMed Web of Science ®Google Scholar
• Hollows F, Moran D. Cataract–the ultraviolet risk factor. Lancet. 1981;2(8258):1249–1250. doi:https://doi.org/10.1016/S0140-6736(81)91490-2.
   PubMed Web of Science ®Google Scholar
• West S. Epidemiology of cataract: accomplishments over 25 years and future directions. Ophthalmic Epidemiol. 2007;14(4):173–178. doi:https://doi.org/10.1080/09286580701423151.
   PubMed Web of Science ®Google Scholar
• Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96(5):614–618. doi:https://doi.org/10.1136/bjophthalmol-2011-300539.
   PubMed Web of Science ®Google Scholar
• Cruickshanks KJ, Klein BE, Klein R. Ultraviolet light exposure and lens opacities: the Beaver dam eye study. Am J Public Health. 1992;82(12):1658–1662. doi:https://doi.org/10.2105/AJPH.82.12.1658.
   PubMed Web of Science ®Google Scholar
• Coroneo MT. Pterygium as an early indicator of ultraviolet insolation: a hypothesis. Br J Ophthalmol. 1993;77(11):734–739. doi:https://doi.org/10.1136/bjo.77.11.734.
   PubMed Web of Science ®Google Scholar
• Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10(4):282–288. doi:https://doi.org/10.1097/00055735-199908000-00011.
   PubMedGoogle Scholar
• Threlfall TJ, English DR. Sun exposure and pterygium of the eye: a dose-response curve. Am J Ophthalmol. 1999;128(3):280–287. doi:https://doi.org/10.1016/S0002-9394(99)00161-0.
   PubMed Web of Science ®Google Scholar
• Taylor HR, West SK, Rosenthal FS, et al. Effect of ultraviolet radiation on cataract formation. N Engl J Med. 1988;319(22):1429–1433. doi:https://doi.org/10.1056/NEJM198812013192201.
   PubMed Web of Science ®Google Scholar
• Hightower KR. A review of the evidence that ultraviolet irradiation is a risk factor in cataractogenesis. Documenta Ophthalmologica. 1994;88(3–4):205–220. doi:https://doi.org/10.1007/BF01203675.
   PubMed Web of Science ®Google Scholar
• Roberts JE. Ultraviolet radiation as a risk factor for cataract and macular degeneration. Eye Contact Lens. 2011;37(4):246–249. doi:https://doi.org/10.1097/ICL.0b013e31821cbcc9.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yan H, Löfgren S, Tian X, Lou MF. Ultraviolet radiation-induced cataract in mice: the effect of age and the potential biochemical mechanism. Invest Ophthalmol Vis Sci. 2012;53(11):7276–7285. doi:https://doi.org/10.1167/iovs.12-10482.
   PubMed Web of Science ®Google Scholar
• Delic NC, Lyons JG, Di Girolamo N, Halliday GM. Damaging effects of ultraviolet radiation on the cornea. Photochem Photobiol. 2017;93(4):920–929. doi:https://doi.org/10.1111/php.2017.93.issue-4.
   PubMed Web of Science ®Google Scholar
• Mureşan S, Filip A, Mureşan A, et al. Histological findings in the Wistar rat cornea following UVB irradiation. Rom J Morphol Embryol. 2013;54(2):247–252.
   PubMed Web of Science ®Google Scholar
• Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016;73(22):4249–4264. doi:https://doi.org/10.1007/s00018-016-2293-z.
   PubMed Web of Science ®Google Scholar
• Suvas S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol. 2017;199(5):1543–1552. doi:https://doi.org/10.4049/jimmunol.1601751.
   PubMed Web of Science ®Google Scholar
• Foldenauer MEB, McClellan SA, Barrett RP, Zhang Y, Hazlett LD. Substance P affects growth factors in Pseudomonas aeruginosa-infected mouse cornea. Cornea. 2012;31(10):1176–1188. doi:https://doi.org/10.1097/ICO.0b013e31824d6ffd.
   PubMed Web of Science ®Google Scholar
• McClellan SA, Zhang Y, Barrett RP, Hazlett LD. Substance P promotes susceptibility to Pseudomonas aeruginosa keratitis in resistant mice: anti-inflammatory mediators downregulated. Invest Ophthalmol Vis Sci. 2008;49(4):1502–1511. doi:https://doi.org/10.1167/iovs.07-1369.
   PubMed Web of Science ®Google Scholar
• Twardy BS, Channappanavar R, Suvas S. Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions. Invest Ophthalmol Vis Sci. 2011;52(12):8604–8613. doi:https://doi.org/10.1167/iovs.11-8089.
   PubMed Web of Science ®Google Scholar
• Hazlett LD, McClellan SA, Barrett RP, Liu J, Zhang Y, Lighvani S. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007;48(2):797–807. doi:https://doi.org/10.1167/iovs.06-0882.
   PubMed Web of Science ®Google Scholar
• Gross J, Wegener AR, Kronschlaeger M, Holz FG, Schönfeld C-L, Meyer LM. Ultraviolet radiation exposure triggers neurokinin-1 receptor upregulation in ocular tissues in vivo. Exp Eye Res. 2018;174:70–79. doi:https://doi.org/10.1016/j.exer.2018.04.016.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kumamoto T, Arima T, et al. Evaluation of aprepitant and Fosaprepitant in pediatric patients. Pediatr Int. 2019;61(3):235–239. doi:https://doi.org/10.1111/ped.2019.61.issue-3.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. Drugs. 2016;76(14):1365–1372. doi:https://doi.org/10.1007/s40265-016-0627-7.
   PubMed Web of Science ®Google Scholar
• Bignami F, Lorusso A, Rama P, Ferrari G. Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment. Acta Ophthalmol. 2017;95(7):e641–e648. doi:https://doi.org/10.1111/aos.13304.
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Gambale J, Jin B, et al. Tolerability of Fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47(7):834–840. doi:https://doi.org/10.1177/0091270007301800.
   PubMed Web of Science ®Google Scholar
• Rosso M, Muñoz M, Berger M. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. Scientific World J. 2012;2012:381434.
   Google Scholar
• Bayati S, Bashash D, Ahmadian S, et al. Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells. Eur J Pharmacol. 2016;791:274–283. doi:https://doi.org/10.1016/j.ejphar.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Coveñas R. Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf. 2013;12(5):673–685. doi:https://doi.org/10.1517/14740338.2013.804059.
   PubMed Web of Science ®Google Scholar
• Barrett JS, Spitsin S, Moorthy G, et al. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med. 2016;14(1):148. doi:https://doi.org/10.1186/s12967-016-0904-y.
   PubMedGoogle Scholar
• Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94(1):265–301. doi:https://doi.org/10.1152/physrev.00031.2013.
   PubMed Web of Science ®Google Scholar
• Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16(12):1977–1985. doi:https://doi.org/10.1517/13543784.16.12.1977.
   PubMed Web of Science ®Google Scholar
• Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008;8(11):1733–1742. doi:https://doi.org/10.1586/14737140.8.11.1733.
   PubMed Web of Science ®Google Scholar
• van Belle SJ, Cocquyt V. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opin Pharmacother. 2008;9(18):3261–3270. doi:https://doi.org/10.1517/14656560802548463.
   PubMed Web of Science ®Google Scholar
• Robinson P, Martin P, Garza A, D’Souza M, Mastrangelo M-A, Tweardy D. Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice. J Parasitol. 2008;94:1150–1154.
   PubMed Web of Science ®Google Scholar
• Martinez AN, Burmeister AR, Ramesh G, Doyle-Meyers L, Marriott I, Philipp MT. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. J Neuroinflammation. 2017;14(1):37. doi:https://doi.org/10.1186/s12974-017-0813-x.
   PubMedGoogle Scholar
• Lönndahl L, Holst M, Bradley M, et al. Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis. Acta Derm Venereol. 2018;98(3):324–328. doi:https://doi.org/10.2340/00015555-2852.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Rosso M, Coveñas R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem. 2010;17(6):504–516. doi:https://doi.org/10.2174/092986710790416308.
   PubMed Web of Science ®Google Scholar
• Berger M, Neth O, Ilmer M, et al. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol. 2014;60(5):985–994. doi:https://doi.org/10.1016/j.jhep.2013.12.024.
   PubMed Web of Science ®Google Scholar
• Harford-Wright E, Lewis KM, Ghabriel MN, Vink R. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors. PloS One. 2014;9(5):e97002. doi:https://doi.org/10.1371/journal.pone.0097002.
   PubMed Web of Science ®Google Scholar
• Gross J, Willimsky E, Wegener AR, et al. Ultraviolet radiation exposure of one eye stimulates sympathizing expression of neurokinin-1 receptor but not monocyte chemoattractant protein-1 in the partner eye. Ophthalmic Res. 2019:1–13. doi:https://doi.org/10.1159/000501320.
   Google Scholar
• Zhou Z, Barrett RP, McClellan SA, et al. Substance P delays apoptosis, enhancing keratitis after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2008;49(10):4458–4467. doi:https://doi.org/10.1167/iovs.08-1906.
   PubMed Web of Science ®Google Scholar
• Lucas K, Karamichos D, Mathew R, Zieske JD, Stein-Streilein J. Retinal laser burn-induced neuropathy leads to substance P-dependent loss of ocular immune privilege. J Immunol. 2012;189(3):1237–1242. doi:https://doi.org/10.4049/jimmunol.1103264.
   PubMed Web of Science ®Google Scholar
• Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides. 1997;31(6):537–563. doi:https://doi.org/10.1016/S0143-4179(97)90001-9.
   PubMed Web of Science ®Google Scholar
• Black AT, Gordon MK, Heck DE, Gallo MA, Laskin DL, Laskin JD. UVB light regulates expression of antioxidants and inflammatory mediators in human corneal epithelial cells. Biochem Pharmacol. 2011;81(7):873–880. doi:https://doi.org/10.1016/j.bcp.2011.01.014.
   PubMed Web of Science ®Google Scholar
• Chao S-C, Hu D-N, Roberts J, et al. Inhibition effect of curcumin on UVB-induced secretion of pro-inflammatory cytokines from corneal limbus epithelial cells. Int J Ophthalmol. 2017;10(6):827–833. doi:https://doi.org/10.18240/ijo.2017.06.01.
   PubMed Web of Science ®Google Scholar
• Chen S-J, Lee C-J, Lin T-B, et al. Inhibition of ultraviolet B-induced expression of the proinflammatory cytokines TNF-α and VEGF in the cornea by fucoxanthin treatment in a rat model. Mar Drugs. 2016;14(1):13. doi:https://doi.org/10.3390/md14010013.
   PubMed Web of Science ®Google Scholar
• Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and −8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2002;43:3430–3437.
   PubMed Web of Science ®Google Scholar
• Solomon A, Li DQ, Lee SB, Tseng SC. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci. 2000;41:2154–2163.
   PubMed Web of Science ®Google Scholar
• Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol. 2000;165(10):5606–5611. doi:https://doi.org/10.4049/jimmunol.165.10.5606.
   PubMed Web of Science ®Google Scholar
• Chen W, Lin H, Zhong X, et al. Discrepant expression of cytokines in inflammation- and age-related cataract patients. PloS One. 2014;9(10):e109647. doi:https://doi.org/10.1371/journal.pone.0109647.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu Y, Zheng W, Qian T, Wang H, Hou X. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Artif Cells Nanomed Biotechnol. 2019;47(1):1628–1634. doi:https://doi.org/10.1080/21691401.2019.1573177.
   PubMed Web of Science ®Google Scholar
• Liu B-K, Jin X-W, Lu H-Z, Zhang X, Zhao Z-H, Shao Y. The effects of neurokinin-1 receptor antagonist in an experimental autoimmune cystitis model resembling bladder pain syndrome/interstitial cystitis. Inflammation. 2019;42(1):246–254. doi:https://doi.org/10.1007/s10753-018-0888-2.
   PubMed Web of Science ®Google Scholar
• Spitsin S, Meshki J, Winters A, Tuluc F, Benton TD, Douglas SD. Substance P-mediated chemokine production promotes monocyte migration. J Leukoc Biol. 2017;101(4):967–973. doi:https://doi.org/10.1189/jlb.1AB0416-188RR.
   PubMed Web of Science ®Google Scholar
• Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000;39(4):652–663. doi:https://doi.org/10.1016/S0028-3908(99)00172-0.
   PubMed Web of Science ®Google Scholar